Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.

Judith van DalemJohanna H M DriessenAndrea M BurdenCoen D A StehouwerOlaf H KlungelFrank de VriesMartijn C G J Brouwers

Published in: Hepatology (Baltimore, Md.) (2021)

Results of our study endorse the use of TZDs for selected patients at risk of NAFLD but do not support previous findings regarding the beneficial effect of GLP-1 receptor agonists. The low number of events in several subgroups may affect the generalizability of the current findings.

Keyphrases